Alcon AG vs iShares MSCI Japan ETF — how do they compare? Alcon AG trades at $72.37 (market cap $36.44B), while iShares MSCI Japan ETF trades at $98.15. The key difference: Alcon AG pays a 0.48% dividend while iShares MSCI Japan ETF pays none, and iShares MSCI Japan ETF is trading nearer its 52-week high, Alcon AG nearer its low. Which is the better fit depends on your goals.
| ALC | EWJ | |
|---|---|---|
Market Cap | $36.44B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $90.12 | $96.97 |
52-Week Low | $62.02 | $77.93 |
Enterprise Value | $40.28B | — |
Dividend Yield | 0.48% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $73.63, up 2.53% today, with a bullish technical signal from moving averages and strong recent earnings beats. Revenue growth is steady, reaching $10.40B in 2025, though net income margin dipped to 5.92%. Positive news includes raised 2026 profit guidance and new product launches driving investor optimism.
The outlook is positive with a consensus price target of $86.67 implying 17.7% upside, supported by analyst buy ratings. Risks include elevated P/E of 57.52 and potential tariff impacts, but operational cash flow strength and strategic collaborations provide a solid foundation for growth.
EWJ (iShares MSCI Japan ETF) trades at $98.12, up 2.16% with strong bullish technical signals from moving averages. The ETF benefits from recent U.S.-Japan currency intervention supporting the yen, while facing headwinds from Japan's inflation dynamics and export pressures. Technical indicators show overbought conditions with RSI at 84.79, suggesting potential near-term consolidation.
Outlook remains cautiously optimistic as Japanese equities respond to policy support, though currency volatility and economic uncertainty present risks. The fund's exposure to Japan's export sector faces challenges from yen strength, while domestic stimulus measures could provide upside potential for consumer-focused holdings.
Trailing returns across standard periods
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →